CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH

CureGene Pharmaceuticals announced preclinical data for its investigational drug, CG-0416, a liver-targeted thyroid hormone receptor beta (THR-β) prod...
Home/KnloSights/Clinical Trial Updates/CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH